Benitec Biopharma (BNTC) to Release Quarterly Earnings on Monday

Benitec Biopharma (NASDAQ:BNTC) is projected to post its quarterly earnings results on Monday, February 10th. Analysts expect Benitec Biopharma to post earnings of ($0.55) per share for the quarter.

Benitec Biopharma Stock Performance

NASDAQ:BNTC opened at $11.49 on Monday. Benitec Biopharma has a 1 year low of $2.70 and a 1 year high of $13.29. The stock has a fifty day moving average price of $11.18 and a two-hundred day moving average price of $10.11. The stock has a market capitalization of $266.75 million, a price-to-earnings ratio of -2.77 and a beta of 0.82.

Insider Activity

In other Benitec Biopharma news, Director Suvretta Capital Management, L bought 27,502 shares of Benitec Biopharma stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $10.98 per share, for a total transaction of $301,971.96. Following the completion of the transaction, the director now owns 7,981,725 shares of the company’s stock, valued at $87,639,340.50. This represents a 0.35 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on BNTC. Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating and set a $17.00 price target on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. JMP Securities lifted their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research report on Monday, October 14th. Finally, Robert W. Baird began coverage on shares of Benitec Biopharma in a research report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $24.43.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.